Unknown

Dataset Information

0

Time to ditch HDL-C as a measure of HDL function?


ABSTRACT: PURPOSE OF REVIEW:Epidemiological and clinical studies link low levels of HDL cholesterol (HDL-C) with increased risk of atherosclerotic cardiovascular disease (CVD). However, genetic polymorphisms linked to HDL-C do not associate consistently with CVD risk, and randomized clinical studies of drugs that elevate HDL-C via different mechanisms failed to reduce CVD risk in statin-treated patients with established CVD. New metrics that capture HDL's proposed cardioprotective effects are therefore urgently needed. RECENT FINDINGS:Recent studies demonstrate cholesterol efflux capacity (CEC) of serum HDL (serum depleted of cholesterol-rich atherogenic lipoproteins) is an independent and better predictor of incident and prevalent CVD risk than HDL-C. However, it remains unclear whether therapies that increase CEC are cardioprotective. Other key issues are the impact of HDL-targeted therapies on HDL particle size and concentration and the relationship of those changes to CEC and cardioprotection. SUMMARY:It is time to end the clinical focus on HDL-C and to understand how HDL's function, protein composition and size contribute to CVD risk. It will also be important to link variations in function and size to HDL-targeted therapies. Developing new metrics for quantifying HDL function, based on better understanding HDL metabolism and macrophage CEC, is critical for achieving these goals.

SUBMITTER: Ronsein GE 

PROVIDER: S-EPMC5659345 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Time to ditch HDL-C as a measure of HDL function?

Ronsein Graziella E GE   Heinecke Jay W JW  

Current opinion in lipidology 20171001 5


<h4>Purpose of review</h4>Epidemiological and clinical studies link low levels of HDL cholesterol (HDL-C) with increased risk of atherosclerotic cardiovascular disease (CVD). However, genetic polymorphisms linked to HDL-C do not associate consistently with CVD risk, and randomized clinical studies of drugs that elevate HDL-C via different mechanisms failed to reduce CVD risk in statin-treated patients with established CVD. New metrics that capture HDL's proposed cardioprotective effects are ther  ...[more]

Similar Datasets

| S-EPMC4803888 | biostudies-literature
| S-EPMC6399512 | biostudies-literature
| S-EPMC8715479 | biostudies-literature
| S-EPMC9990217 | biostudies-literature
| S-EPMC9138557 | biostudies-literature
| S-EPMC3617479 | biostudies-literature
| S-EPMC7137123 | biostudies-literature
| S-EPMC8105263 | biostudies-literature
| S-EPMC3361641 | biostudies-literature
2019-08-12 | PXD010199 | Pride